BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Given Consensus Rating of “Hold” by Analysts

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) has earned an average recommendation of “Hold” from the four brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $11.00.

A number of research analysts have issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of BioXcel Therapeutics in a research report on Friday, July 17th. Wall Street Zen cut shares of BioXcel Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th.

Institutional Trading of BioXcel Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of BTAI. Millennium Management LLC bought a new stake in BioXcel Therapeutics during the 3rd quarter valued at approximately $2,632,000. Jane Street Group LLC bought a new position in shares of BioXcel Therapeutics in the 4th quarter worth approximately $204,000. Geode Capital Management LLC raised its position in shares of BioXcel Therapeutics by 64.6% in the 4th quarter. Geode Capital Management LLC now owns 206,168 shares of the company’s stock worth $330,000 after acquiring an additional 80,928 shares in the last quarter. Man Group plc purchased a new position in shares of BioXcel Therapeutics in the 4th quarter valued at approximately $91,000. Finally, Headlands Technologies LLC purchased a new position in shares of BioXcel Therapeutics in the 2nd quarter valued at approximately $36,000. 30.68% of the stock is currently owned by hedge funds and other institutional investors.

BioXcel Therapeutics Stock Performance

Shares of BTAI stock opened at $0.72 on Friday. BioXcel Therapeutics has a fifty-two week low of $0.70 and a fifty-two week high of $4.29. The firm has a market cap of $22.51 million, a P/E ratio of -0.19 and a beta of 0.31. The business’s 50 day moving average price is $0.98 and its 200-day moving average price is $1.20.

BioXcel Therapeutics (NASDAQ:BTAI) last announced its earnings results on Thursday, August 13th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). The company had revenue of $0.18 million during the quarter, compared to the consensus estimate of $0.48 million. As a group, equities analysts predict that BioXcel Therapeutics will post -2.11 EPS for the current year.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.